Zhang W, Bai Y, Sun C, et al. Racial and regional disparities of triple negative breast cancer incidence rates in the United States: an analysis of 2011–2019 NPCR and SEER incidence data. Front Public Health. 2022;10:1058722.

Article  PubMed  PubMed Central  Google Scholar 

Punie K, Kurian AW, Ntalla I et al. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States. Oncologist 30, 2025.

Grinda T, Antoine A, Jacot W, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008–2017 ESME cohort. ESMO Open. 2021;6:100114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu JY, Chang CJ, Cheng JS. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Sci Rep. 2022;12:729.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Celik A, Berg T, Jensen MB, et al. Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer. Breast Cancer (Auckl). 2023;17:11782234231203292.

Article  PubMed  PubMed Central  Google Scholar 

Hammerl D, Martens JWM, Timmermans M, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12:5668.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304–11.

Article  CAS  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384:2394–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood SJ, Gao Y, Lee JH, et al. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Res Treat. 2024;205:193–9.

Article  CAS  PubMed  Google Scholar 

Loi S, Salgado R, Schmid P, et al. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO Precis Oncol. 2023;7:e2200317.

Article  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529–41.

Article  CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387:217–26.

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 2.2026.

Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026;394:354–66.

Article  CAS  PubMed  Google Scholar 

Schmid P, Oliveira M, O’Shaughnessy J, et al. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251327992.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Danziger N, Sokol ES, Graf RP, et al. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. Oncologist. 2023;28:319–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393:1912–25.

Article  CAS  PubMed  Google Scholar 

Dent RA, Cescon DW, Bachelot T, et al. TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023;19:2349–59.

Article  CAS  PubMed  Google Scholar 

Dent RA, Shao Z, Schmid P, et al. LBA21 first-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: primary results from the randomised, phase III TROPION-Breast02 trial. Ann Oncol. 2025;36:S1566–7.

Article  Google Scholar 

Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang K, Wang S. Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review. Transl Breast Cancer Res. 2025;6:9.

Article  PubMed  PubMed Central  Google Scholar 

Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Cheng X, Li X, et al. Bystander effect in antibody-drug conjugates: navigating the fine line in tumor heterogeneity. Crit Rev Oncol Hematol. 2025;216:104979.

Article  PubMed  Google Scholar 

Modi S, Salgado R, Guarneri V et al. Abstract PO2-19-06: An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15. Cancer Res 84:PO2-19-06-PO2-19-06, 2024.

Zeng P, Chen MB, Zhou LN, et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919–31.

Article  CAS  PubMed  Google Scholar 

Shastry M, Jacob S, Rugo HS, et al. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169–77.

Article  PubMed  PubMed Central  Google Scholar 

Schmid P, Wang HC, Lynce F, et al. 555MO datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): final results from the phase Ib/II BEGONIA study. Ann Oncol. 2025;36:S413–4.

Article  Google Scholar 

Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10:227–35.

Article  PubMed  PubMed Central  Google Scholar 

Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113:1005–16.

Article  PubMed  PubMed Central